<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31112030</article-id><article-id pub-id-type="pmc">6852442</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0323</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Does CHA<sub>2</sub>DS<sub>2</sub>-VASc Score Predict MACE in
Patients Undergoing Isolated Coronary Artery Bypass Grafting
Surgery?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kalyoncuoglu</surname><given-names>Muhsin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5696-6849</contrib-id><name><surname>Ozturk</surname><given-names>Semi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Sahin</surname><given-names>Mazlum</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib></contrib-group><aff id="aff1">
<label>1</label>Department of Cardiology, Haseki Training and Research Hospital,
Istanbul, Turkey.</aff><aff id="aff2">
<label>2</label>Department of Cardiovascular Surgery, Haseki Training and Research
Hospital, Istanbul, Turkey.</aff><author-notes><corresp id="c1">Correspondence Address: <bold>Semi Ozturk</bold>, <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-5696-6849">https://orcid.org/0000-0001-5696-6849</ext-link>, Haseki Training and
Research Hospital, Department of Cardiology, Millet Caddesi No: 9, Aksaray,
Fatih, Istanbul, Turkey, Z&#x00131;p Code: 34130. E-mail:
<email>semi_ozturk@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2019</year></pub-date><volume>34</volume><issue>5</issue><fpage>542</fpage><lpage>549</lpage><history><date date-type="received"><day>11</day><month>10</month><year>2018</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2019</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To evaluate the prognostic value of CHA<sub>2</sub>DS<sub>2</sub>-VASc score
in individuals undergoing isolated coronary artery bypass grafting (CABG)
surgery.</p></sec><sec><title>Methods</title><p>Records of consecutive 464 patients who underwent elective isolated CABG,
between January 2015 and August 2017, were retrospectively reviewed. A major
adverse cardiac event (MACE) was the primary outcome of this study. MACE in
patients with low (L) (&#x0003c;2, n: 238) and high (H) (&#x02264;2, n: 226)
CHA<sub>2</sub>DS<sub>2</sub>-VASc scores were compared. Univariate
logistic regression analysis identified preditors of MACE.</p></sec><sec><title>Results</title><p>Hypertension, diabetes mellitus, and peripheral vascular disease were more
frequent in the H group than in the L group. European System for Cardiac
Operative Risk Evaluation (EuroSCORE) I and SYNTAX I scores were similar in
both groups while SYNTAX II-CABG score was significantly higher in the H
group than in the L group. Postoperative myocardial infarction, need for
intra-aortic balloon pump, acute renal failure, and mediastinitis were more
frequent in the H group than in the L group. The H group had significantly
higher in-hospital mortality and MACE rates than the L group
(<italic>P</italic>&#x0003c;0.01). EuroSCORE I, SYNTAX II-CABG, and
CHA<sub>2</sub>DS<sub>2</sub>-VASc scores were predictors for MACE.
SYNTAX II-CABG &#x0003e; 25.1 had 68.4% sensitivity and 52.7% specificity (area
under the curve [AUC]: 0.653, <italic>P</italic>=0.04, 95%
confidence interval [CI]: 0.607-0.696) and
CHA<sub>2</sub>DS<sub>2</sub>-VASc &#x0003e; 2 had 52.6% sensitivity and
84.1% specificity (AUC: 0.752, <italic>P</italic>&#x0003c;0.01, 95% CI:
0.710-0.790) to predict MACE. Pairwise comparison of receiver-operating
characteristic curves revealed similar accuracy for both scoring
systems.</p></sec><sec><title>Conclusion</title><p>CHA<sub>2</sub>DS<sub>2</sub>-VASc score may predict MACE in patients
undergoing isolated CABG.</p></sec></abstract><kwd-group><kwd>Coronary Artery Disease</kwd><kwd>Coronary Artery Bypass &#x02013; adverse effects</kwd><kwd>Lenght of Stay &#x02013; trends</kwd><kwd>Time Factors</kwd></kwd-group></article-meta></front><body><table-wrap id="t1" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th rowspan="1" colspan="1">&#x000a0;</th><th colspan="2" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Acute coronary
syndrome</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive care unit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Atrial fibrillation</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IQR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Interquartile range</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AUC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Area under the
curve</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">L</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Low</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BMI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Body mass index</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LDL-C</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Low-density lipoprotein
cholesterol</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CAD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery
disease</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MACE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Major adverse cardiac
event</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Confidence interval</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Myocardial
infarction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">COPD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Chronic obstructive
pulmonary disease</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Odds ratio</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PAD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Peripheral artery
disease</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CRP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= C-reactive protein</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PCI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Percutaneous coronary
intervention</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Diabetes mellitus</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PVD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Peripheral vascular
disease</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EuroSCORE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= European System for
Cardiac Operative Risk Evaluation</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ROC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Receiver-operating
characteristic</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">H</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= High</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard deviation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HDL-C</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= High-density lipoprotein
cholesterol</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard error</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">Ht</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hypertension</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SPSS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Statistical Package for
the Social Sciences</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Heart
transplantation</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">STS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Society of Thoracic
Surgeons</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IAB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intra-aortic
balloon</td><td rowspan="1" colspan="1"/><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TAVR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transcatheter aortic
valve replacement</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Coronary artery bypass grafting (CABG) surgery and percutaneous coronary intervention
(PCI) are widely used revascularization strategies for coronary artery disease (CAD)
which reduce mortality and improve quality of life<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Recent data suggested the superiority of
CABG in preventing major cardiac events in patients with multivessel disease,
particularly in patients with complex CAD and diabetes<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.</p><p>The European System for Cardiac Operative Risk Evaluation (EuroSCORE) and the Society
of Thoracic Surgeons (STS) 2008 Cardiac Surgery Risk Model are the most commonly
used risk prediction models for cardiac surgery. These scoring systems are not only
useful to assess the effect of specific clinical parameters on surgical outcomes,
but also to aid in treatment selection, patient counseling, comparison of
postoperative results, and quality improvement<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Besides, current mortality risk prediction
models for CABG do not have a standardized approach in terms of both defining
predictor variables and outcome. In addition, some problematic topics such as
inadequate sample size, inappropriate handling of missing data, as well as
suboptimal statistical techniques make these risk models debatable<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Need for calculator or
computer make these models impractical for daily clinical use. Therefore, more
practical risk modeling systems which predict morbidity and mortality are
required.</p><p>CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores are well-validated
and proposed scoring systems to establish the risk of stroke in patients with
non-valvular atrial fibrillation (AF). Additionally,
CHA<sub>2</sub>DS<sub>2</sub>-VASc score components, such as age, hypertension,
diabetes mellitus (DM), and prior cardiovascular event, are also traditional risk
factors for CAD. Previous studies demonstrated the association between the
CHA<sub>2</sub>DS<sub>2</sub>-VASc score and the severity of
CAD<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.
Recent studies demonstrated the prognostic value of the
CHA<sub>2</sub>DS<sub>2</sub>-VASc score in patients suffering from acute
coronary syndrome (ACS)<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>Although CHA<sub>2</sub>DS<sub>2</sub>-VASc score is proposed as a predictor for
immediate and late stroke after CABG, there is no data evaluating the prognostic
value of CHA<sub>2</sub>DS<sub>2</sub>-VASc score in patients undergoing isolated
CABG surgery<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. When
compared with the aforementioned risk models, the CHA<sub>2</sub>DS<sub>2</sub>-VASc
score is a fast and simple method for risk evaluation that requires no calculator or
computers. We sought for the prognostic value of CHA<sub>2</sub>DS<sub>2</sub>-VASc
score in individuals undergoing isolated CABG surgery.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study Population</title><p>This study included patients who underwent isolated CABG at the Haseki Training
and Research Hospital between January 2015 and August 2017. The study excluded
patients with concomitant other surgeries such as valve repair or replacement.
Patients with preoperative AF were also excluded. Emergent procedures were
excluded since preoperative assessments, such as carotid ultrasound, were
insufficient. Records of 555 patients were retrospectively reviewed. Of these,
22 (3.9%) patients had an insufficient record, 14 (2.5%) underwent off-pump
surgery, and 23 (4.1%) underwent concomitant other cardiac surgery (valvular,
ventricular aneurysms, acquired ventricular septal defect). Additional 32 (5.8%)
patients who underwent emergent surgery were excluded from the study. All
patients were operated by the same group of cardiovascular surgeons and
anesthesiologists. Same techniques during CABG and myocardial protection were
used.</p><p>The study population was retrospectively and consecutively analyzed by using our
database, which was collected as a part of routine clinical practice. Data from
each patient were obtained from a computerized system or a patient file.
Demographic and laboratory variables including age, gender, body mass index
(BMI), C-reactive protein, lipid panel, and clinical variables during
hospitalization were recorded. Clinical variables included cardiopulmonary
bypass (CPB) time, need for intra-aortic balloon (IAB), clamp time, total number
of grafts, extubation time, bleeding revision, perioperative myocardial
infarction (MI), sternal dehiscence, wound infection, cerebrovascular event
(stroke or transient ischemic attack), mediastinitis, acute kidney injury, acute
AF (lasting longer than one hour), intensive care unit (ICU) time,
hospitalization time, and in-hospital mortality.</p></sec><sec><title>Risk Scores</title><sec><title>SYNTAX I-II Score</title><p>The angiograms of the patients were evaluated by two experienced
interventional cardiologists who were blind to the study. CAD was defined as
a stenosis of more than 50% of the lumen diameter in any of the main
coronary arteries. SYNTAX I-II scores were calculated by using the
downloaded version (<ext-link ext-link-type="uri" xlink:href="http://www.syntaxscore.com">www.syntaxscore.com</ext-link>).</p></sec><sec><title>EuroSCORE I</title><p>Preoperative risk stratification was performed for all patients by using the
downloaded version of the EuroSCORE system (<ext-link ext-link-type="uri" xlink:href="http://euroscore.org">euroscore.org</ext-link>).</p></sec><sec><title>CHA<sub>2</sub>DS<sub>2</sub>-VASc Score</title><p>CHA<sub>2</sub>DS<sub>2</sub>-VASc score was calculated for all patients by
assigning one point for each of the following criteria: age 65-75 years,
hypertension, DM, congestive heart failure or left ventricular ejection
fraction (LVEF) &#x0003c; 40%, female sex, and vascular disease (defined as prior
MI, complex aortic plaque, carotid disease, peripheral artery disease
including intermittent claudication, and previous surgical or percutaneous
intervention for abdominal aorta or vessels of upper or lower extremities).
Two points were assigned for a history of stroke or transient ischemic
attack or thromboembolism and age &#x02265; 75 years. Since all patients
underwent coronary bypass surgery due to multiple CAD, CAD at index
hospitalization was not taken into account. After the
CHA<sub>2</sub>DS<sub>2</sub>-VASc score calculation, the study
population was divided into two groups: low (L)
(CHA<sub>2</sub>DS<sub>2</sub>-VASc &#x0003c;2 ) and high (H)
(CHA<sub>2</sub>DS<sub>2</sub>-VASc &#x02265; 2) score groups.</p></sec></sec><sec><title>Study Endpoints</title><p>A major adverse cardiac event (MACE) was the primary endpoint of this study. MACE
was defined as a composite of in-hospital mortality, postoperative non-fatal MI,
cardiac arrest requiring cardiopulmonary resuscitation, need for new mechanical
circulatory support, and cerebrovascular event during
intraoperative/postoperative hospitalization. In-hospital mortality was defined
as death from all causes during intraoperative and postoperative
hospitalization. The study was approved by the local ethics committee.</p></sec><sec><title>Statistical Analysis</title><p>Statistical analyses were performed with Statistical Package for the Social
Sciences (SPSS) software version 22.0 (IBM Corp. Armonk, New York, United States
of America) and MedCalc bvba version 16 (Seoul, Korea). Normality of the data
was analyzed with the Kolmogorov-Smirnov test. Continuous data were expressed as
mean &#x000b1; standard deviation (SD) and categorical data were expressed as
percentages. Categorical variables between the groups were assessed with
Chi-square test or Fisher&#x02019;s exact test, whichever was suitable. Logistic
regression analysis was used to identify the independent predictors of MACE.
Differences between patient subgroups were tested using Mann-Whitney U test or
Student's t-test, where appropriate. A <italic>P</italic>-value &#x0003c; 0.05 was
considered statistically significant. Receiver-operating characteristic (ROC)
curve graphics were used to determine the cut-off values of predictors for
MACE.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Four hundred sixty-four patients who underwent elective isolated CABG surgery were
included in the study. Patients were dichotomized depending on their
CHA<sub>2</sub>DS<sub>2</sub>-VASc score. L and H score groups were compared as
previously described. The L group included 238 patients (median age: 57 years
[interquartile range {IQR}: 52-63]; 44 [18.5%] females)
while the H group included 226 patients (median age: 64 years [IQR:
55-67]; 45 [19.9%] females). Hypertension, DM, and peripheral
vascular disease (PVD) were more frequent in the H group
(<italic>P</italic>&#x0003c;0.001, <italic>P</italic>&#x0003c;0.001, <italic>P</italic>=0.044,
respectively) than in the L group. EuroSCORE I was similar in both groups
(<italic>P</italic>=0.53). Anatomical based SYNTAX I score was similar in both
groups, while clinical SYNTAX II-CABG score was significantly higher in the H group
than in the L group (<italic>P</italic>=0.4, <italic>P</italic>=0.001,
respectively). Postoperative MI was more frequent in the H group
(<italic>P</italic>=0.006) than in the L group. Patients in the H group needed more
&#x00130;AB pump support (<italic>P</italic>=0.005) than those in the L group. Acute
renal failure and mediastinitis in the postoperative period were more frequent in H
group (<italic>P</italic>&#x0003c;0.001, <italic>P</italic>&#x0003c;0.001, respectively) than
in the L group. Clinical, laboratory, and operative parameters were presented in
<xref rid="t2" ref-type="table">Table 1</xref> and <xref rid="t3" ref-type="table">Table 2</xref>. The H group had significantly higher in-hospital
mortality and MACE rates than the L group (<italic>P</italic>&#x0003c;0.01).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic, clinical, and laboratory characteristics of the groups.</p></caption><table frame="box" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" style="border-left:hidden" colspan="1">&#x000a0;</th><th align="center" colspan="2" rowspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc</th><th align="center" rowspan="2" style="border-right:hidden" colspan="1"><italic>P</italic></th></tr><tr><th align="center" rowspan="1" colspan="1">&#x0003c;2 n=238</th><th align="center" rowspan="1" colspan="1">&#x02264;2 n=226</th></tr></thead><tbody><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Sex (female), n (%)</td><td align="center" rowspan="1" colspan="1">44 (18.5)</td><td align="center" rowspan="1" colspan="1">45 (19.9)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">57 (52-63)</td><td align="center" rowspan="1" colspan="1">64 (55-67)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Body mass index
(kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">27 (24.3-29.7)</td><td align="center" rowspan="1" colspan="1">26.4 (24.2-29.5)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Smoking, n (%)</td><td align="center" rowspan="1" colspan="1">99 (41.6)</td><td align="center" rowspan="1" colspan="1">82 (36.3)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">DM, n (%)</td><td align="center" rowspan="1" colspan="1">19 (8)</td><td align="center" rowspan="1" colspan="1">143 (63.3)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Ht, n (%)</td><td align="center" rowspan="1" colspan="1">38 (16)</td><td align="center" rowspan="1" colspan="1">147 (65)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">COPD, n (%)</td><td align="center" rowspan="1" colspan="1">34 (14.3)</td><td align="center" rowspan="1" colspan="1">38 (16.8)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">PAD, n (%)</td><td align="center" rowspan="1" colspan="1">14 (5.9)</td><td align="center" rowspan="1" colspan="1">43 (19)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.044</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">CAD, n (%)</td><td align="center" rowspan="1" colspan="1">36 (15.1)</td><td align="center" rowspan="1" colspan="1">41 (18.1)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Stroke or transient ischemic
attack, n (%)</td><td align="center" rowspan="1" colspan="1">14 (5.9)</td><td align="center" rowspan="1" colspan="1">9 (4)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">55 (50-60)</td><td align="center" rowspan="1" colspan="1">45 (40-60)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Total cholesterol</td><td align="center" rowspan="1" colspan="1">240 (200-356)</td><td align="center" rowspan="1" colspan="1">226 (208-310)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">LDL-C</td><td align="center" rowspan="1" colspan="1">116 (99.5-175)</td><td align="center" rowspan="1" colspan="1">116 (100-175)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">HDL-C</td><td align="center" rowspan="1" colspan="1">45 (42-49)</td><td align="center" rowspan="1" colspan="1">45 (42-51.8)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">CRP</td><td align="center" rowspan="1" colspan="1">5.5 (4-10)</td><td align="center" rowspan="1" colspan="1">5 (4-9)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">EuroSCORE I</td><td align="center" rowspan="1" colspan="1">3 (2-4)</td><td align="center" rowspan="1" colspan="1">3 (2-4)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">SYNTAX I</td><td align="center" rowspan="1" colspan="1">19 (14-25.5)</td><td align="center" rowspan="1" colspan="1">19 (13-23.5)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">SYNTAX II-CABG</td><td align="center" rowspan="1" colspan="1">23.8 (21.3-28)</td><td align="center" rowspan="1" colspan="1">25.7 (21.7-35)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>CABG=coronary artery bypass grafting; CAD=coronary artery disease;
COPD=chronic obstructive pulmonary disease; CRP=Creactive protein;
DM=diabetes mellitus; EuroSCORE=European System for Cardiac Operative
Risk Evaluation; HDL-C=high-density lipoprotein cholesterol;
Ht=hypertension; LDL-C=low-density lipoprotein cholesterol;
PAD=peripheral artery disease</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 2</label><caption><p>Operative and postoperative parameters of the groups. </p></caption><table frame="box" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" style="border-left:hidden" colspan="1">&#x000a0;</th><th align="center" colspan="2" rowspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc</th><th align="center" rowspan="2" style="border-right:hidden" colspan="1">
<italic>P</italic></th></tr><tr><th align="center" rowspan="1" colspan="1">&#x0003c;2 n=238</th><th align="center" rowspan="1" colspan="1">&#x02264;2 n=226</th></tr></thead><tbody><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Bypass number</td><td align="center" rowspan="1" colspan="1">3 (2-3)</td><td align="center" rowspan="1" colspan="1">3 (2-3)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">CPB time (min)</td><td align="center" rowspan="1" colspan="1">92.5 (47-96)</td><td align="center" rowspan="1" colspan="1">91 (47-96)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Clamp time (min)</td><td align="center" rowspan="1" colspan="1">50 (26-55)</td><td align="center" rowspan="1" colspan="1">48 (26-56)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Intra-aortic balloon pump, n
(%)</td><td align="center" rowspan="1" colspan="1">3 (1.3)</td><td align="center" rowspan="1" colspan="1">14 (6.2)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Extubation time (hours)</td><td align="center" rowspan="1" colspan="1">7 (5-9.5)</td><td align="center" rowspan="1" colspan="1">7 (5-10)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Bleeding revision, n
(%)</td><td align="center" rowspan="1" colspan="1">9 (3.8)</td><td align="center" rowspan="1" colspan="1">14 (6.2)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Hemorrhage (ml)</td><td align="center" rowspan="1" colspan="1">500 (350-600)</td><td align="center" rowspan="1" colspan="1">450 (350-600)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Sternal dehiscence, n
(%)</td><td align="center" rowspan="1" colspan="1">13 (5.5)</td><td align="center" rowspan="1" colspan="1">10 (4.4)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.724</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Wound &#x00131;nfection, n
(%)</td><td align="center" rowspan="1" colspan="1">12 (5)</td><td align="center" rowspan="1" colspan="1">12 (5.3)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Mediastinitis, n (%)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">12 (5.3)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Acute renal failure, n
(%)</td><td align="center" rowspan="1" colspan="1">1 (0.4)</td><td align="center" rowspan="1" colspan="1">14 (6.2)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Acute atrial fibrillation, n
(%)</td><td align="center" rowspan="1" colspan="1">27 (11.3)</td><td align="center" rowspan="1" colspan="1">25 (11.1)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Transient ischemic attack, n
(%)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">4 (1.9)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.056</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Stroke, n (%)</td><td align="center" rowspan="1" colspan="1">1 (0.4)</td><td align="center" rowspan="1" colspan="1">4 (1.8)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Post-operative MI, n
(%)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">7 (3.1)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">In-hospital mortality, n
(%)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">14 (6.2)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">MACE, n (%)</td><td align="center" rowspan="1" colspan="1">1 (0.4)</td><td align="center" rowspan="1" colspan="1">18 (8)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Intensive care unit time
(day)</td><td align="center" rowspan="1" colspan="1">2 (2-2)</td><td align="center" rowspan="1" colspan="1">2 (2-3)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">Hospitalization time
(day)</td><td align="center" rowspan="1" colspan="1">5 (5-6)</td><td align="center" rowspan="1" colspan="1">5 (5-6)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.23</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>CPB=cardiopulmonary bypass; MACE=major adverse cardiac events;
MI=myocardial infarction</p></fn></table-wrap-foot></table-wrap><p>When each component of CHA<sub>2</sub>DS<sub>2</sub>-VASc score was analyzed in
univariate logistic regression analysis, congestive heart failure or ejection
fraction &#x0003c; 40%, age, hypertension, PVD, and cerebrovascular event were
independent predictors for MACE (<xref rid="t4" ref-type="table">Table
3</xref>).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 3</label><caption><p> Logistic regression of each CHA<sub>2</sub>DS<sub>2</sub>-Vasc score
component for MACE. </p></caption><table frame="box" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="border-left:hidden" rowspan="1">Variables</th><th align="center" colspan="2" rowspan="1">
<italic>P</italic></th><th align="center" colspan="2" style="border-right:hidden" rowspan="1">OR (95%
CI)</th></tr></thead><tbody><tr><td align="left" colspan="2" style="border-left:hidden" rowspan="1">Congestive heart
failure or ejection fraction &#x0003c; 40%</td><td align="center" colspan="2" rowspan="1">&#x0003c;0.001</td><td align="center" colspan="2" style="border-right:hidden" rowspan="1">12.3 (3.37-
44.87)</td></tr><tr><td align="left" colspan="2" style="border-left:hidden" rowspan="1">Sex</td><td align="center" colspan="2" rowspan="1">0.87</td><td align="center" colspan="2" style="border-right:hidden" rowspan="1">&#x000a0;</td></tr><tr><td align="left" colspan="2" style="border-left:hidden" rowspan="1">Age</td><td align="center" colspan="2" rowspan="1">0.01</td><td align="center" colspan="2" style="border-right:hidden" rowspan="1">1.13
(1.03-1.24)</td></tr><tr><td align="left" colspan="2" style="border-left:hidden" rowspan="1">Hypertension</td><td align="center" colspan="2" rowspan="1">0.008</td><td align="center" colspan="2" style="border-right:hidden" rowspan="1">5.68
(1.56-20.61)</td></tr><tr><td align="left" colspan="2" style="border-left:hidden" rowspan="1">Diabetes
mellitus</td><td align="center" colspan="2" rowspan="1">0.08</td><td align="center" colspan="2" style="border-right:hidden" rowspan="1">&#x000a0;</td></tr><tr><td align="left" colspan="2" style="border-left:hidden" rowspan="1">Cerebrovascular
event (stroke or transient ischemic attack)</td><td align="center" colspan="2" rowspan="1">&#x0003c;0.001</td><td align="center" colspan="2" style="border-right:hidden" rowspan="1">11.42
(3.5-37.28)</td></tr><tr><td align="left" colspan="2" style="border-left:hidden" rowspan="1">Peripheral
vascular disease</td><td align="center" colspan="2" rowspan="1">0.01</td><td align="center" colspan="2" style="border-right:hidden" rowspan="1">4.37
(1.4-1.52)</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>CI=confidence interval; OR= <italic>odds ratio</italic>
</p></fn></table-wrap-foot></table-wrap><p>We performed univariate analysis including EuroSCORE I, SYNTAX I and SYNTAX II, and
CHA<sub>2</sub>DS<sub>2</sub>-VASc scores. EuroSCORE, SYNTAX II-CABG, and
CHA<sub>2</sub>DS<sub>2</sub>-VASc scores were the predictors for MACE in
logistic regression analysis (Hosmer-Lemeshow test, <italic>P</italic>=0.414, 0.941,
and 0.693, and Nagelkerke R Square, <italic>P</italic>=0.359, 0.047, 0.105;
respectively) (<xref rid="t5" ref-type="table">Table 4</xref>). ROC curve analysis
of SYNTAX II-CABG and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores were performed to
predict MACE (<xref ref-type="fig" rid="f1">Figure 1</xref>). SYNTAX II-CABG &#x0003e;
25.1 had 68.4% sensitivity and 52.7% specificity to predict MACE (area under the
curve [AUC]: 0.653, <italic>P</italic>=0.04, 95% confidence interval
[CI]: 0.607-0.696). CHA<sub>2</sub>DS<sub>2</sub>-VASc &#x0003e; 2 had
52.6% sensitivity and 84.1% specificity to predict MACE (AUC: 0.752,
<italic>P</italic>&#x0003c;0.01, 95% CI: 0.710-0.790) (<xref rid="t6" ref-type="table">Table 5</xref>). We compared CHA<sub>2</sub>DS<sub>2</sub>-VASc with
SYNTAX II-CABG, which is a relatively and comprehensive score. Pairwise comparison
of ROC curves revealed the similar statistical accuracy of both scoring systems for
prediction of MACE (Z statistic: 1.097, <italic>P</italic>=0.27) (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p><table-wrap id="t5" orientation="portrait" position="float"><label>Table 4</label><caption><p> Predictors of major adverse cardiac events; univariate logistic regression
analysis of CHA<sub>2</sub>DS<sub>2</sub>-VASc, SYNTAX I, and SYNTAX II
scores. </p></caption><table frame="box" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" style="border-left:hidden" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Univariate analysis OR (95% CI)</th><th align="center" style="border-right:hidden" rowspan="1" colspan="1"><italic>P </italic>
value</th></tr></thead><tbody><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">SYNTAX I</td><td align="center" rowspan="1" colspan="1">1.00 (0.98-1.03)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">SYNTAX II-PCI</td><td align="center" rowspan="1" colspan="1">1.01 (0.99-1.02)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">SYNTAX II-CABG</td><td align="center" rowspan="1" colspan="1">1.07 (1.02-1.12)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">EuroSCORE I</td><td align="center" rowspan="1" colspan="1">2.71 (1.95-3.75)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="border-left:hidden" rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc</td><td align="center" rowspan="1" colspan="1">2.03 (1.41-2.92)</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>CABG=coronary artery bypass grafting; CI=confidence interval;
EuroSCORE=European System for Cardiac Operative Risk Evaluation; OR=
<italic>odds ratio</italic> ; PCI=percutaneous coronary
intervention</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6" orientation="portrait" position="float"><label>Table 5</label><caption><p> Sensitivity and specifity of CHA<sub>2</sub>DS<sub>2</sub>-VASc to predict
MACE. </p></caption><table frame="box" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="center" style="border-left:hidden" rowspan="1" colspan="1">Criterion</th><th align="center" rowspan="1" colspan="1">Sensitivity</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" style="border-right:hidden" rowspan="1" colspan="1">Specificity</th></tr></thead><tbody><tr><td align="center" style="border-left:hidden" rowspan="1" colspan="1">&#x02265;0</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">82.4-100</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">0.00</td></tr><tr><td align="center" style="border-left:hidden" rowspan="1" colspan="1">&#x0003e;0</td><td align="center" rowspan="1" colspan="1">94.74</td><td align="center" rowspan="1" colspan="1">74.0-99.9</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">19.96</td></tr><tr><td align="center" style="border-left:hidden" rowspan="1" colspan="1">&#x0003e;1</td><td align="center" rowspan="1" colspan="1">84.21</td><td align="center" rowspan="1" colspan="1">60.4-96.6</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">55.38</td></tr><tr><td align="center" style="border-left:hidden" rowspan="1" colspan="1">&#x0003e;2</td><td align="center" rowspan="1" colspan="1">52.63</td><td align="center" rowspan="1" colspan="1">28.9-75.6</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">84.08</td></tr><tr><td align="center" style="border-left:hidden" rowspan="1" colspan="1">&#x0003e;3</td><td align="center" rowspan="1" colspan="1">15.79</td><td align="center" rowspan="1" colspan="1">3.4-39.6</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">95.96</td></tr><tr><td align="center" style="border-left:hidden" rowspan="1" colspan="1">&#x0003e;4</td><td align="center" rowspan="1" colspan="1">5.26</td><td align="center" rowspan="1" colspan="1">0.1-26.0</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">98.88</td></tr><tr><td align="center" style="border-left:hidden" rowspan="1" colspan="1">&#x0003e;5</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.0-17.6</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">99.78</td></tr><tr><td align="center" style="border-left:hidden" rowspan="1" colspan="1">&#x0003e;6</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.0-17.6</td><td align="center" style="border-right:hidden" rowspan="1" colspan="1">100</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>CI=confidence interval; MACE=major adverse cardiac event </p></fn></table-wrap-foot></table-wrap><p><fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Receiver-operating characteristic curve analysis of SYNTAX II-CABG and
CHA<sub>2</sub>DS<sub>2</sub>-VASc for prediction of a major adverse
cardiac event. AUC=area under the curve; CABG=coronary artery bypass
grafting; CI=confidence interval</p></caption><graphic xlink:href="rbccv-34-05-0542-g01"/></fig>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Pairwise comparison of receiver-operating characteristic curves of SYNTAX
II-CABG and CHA<sup>2</sup>DS<sub>2</sub>-VASc for prediction of a major
adverse cardiac event. CABG=coronary artery bypass grafting;
CI=confidence interval; SE=Standard error</p></caption><graphic xlink:href="rbccv-34-05-0542-g02"/></fig></p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>We demonstrated, for the first time, that CHA<sub>2</sub>DS<sub>2</sub>-VASc score is
an independent predictor for MACE in patients undergoing isolated CABG. Although
CHA<sub>2</sub>DS<sub>2</sub>-VASc score includes only clinical parameters, it
is as accurate as SYNTAX II-CABG, which includes a detailed angiographic
evaluation.</p><p>CABG is a safe procedure with low rates of mortality and morbidity. However, the
ability to accurately predict adverse outcomes and short- and long-term mortalities
after CABG is an important issue that may allow planning preventive strategies and
minimize complications<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. EuroSCORE, STS risk calculator, and Parsonnet score are
the most commonly used risk stratification models which include multiple variables,
requiring online calculators for estimation of risk-related mortality and morbidity
with CABG<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.
Nevertheless, these are complex and impractical tools to use at the bedside.
Therefore, we still need models to quickly and easily predict risk at bedside,
without the need for computational software. In practice, the bedside risk
assessment not only provides the surgeon an objective, measurable risk profile to
identify patients who require meticulous care, but it also provides the patients a
more detailed knowledge of the risk related with the surgical
procedure<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>CHA<sub>2</sub>DS<sub>2</sub>-VASc score is an easily applicable time-saving risk
model which predicts the risk of thromboembolic events in patients with non-valvular
AF in daily practice. CHA<sub>2</sub>DS<sub>2</sub>-VASc score components, such as
older age, female gender, hypertension, DM, extracardiac arteriopathy, low LVEF, and
preoperative stroke, and the presence of CAD were reported as predictors of early
outcomes after CABG<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>The female sex has been reported as an independent predictor of short- and long-term
mortalities and adverse events after CABG<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Although the female sex is included in
both STS and EuroSCORE, evidence is controversial. Several studies concluded that
the female sex is not a risk factor for post procedural mortality after
CABG<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. In
our study, the female sex was not found to be associated with MACE, which is
compatible with previous studies.</p><p>Increased age (&#x0003e; 60 years) has been reported as an independent predictor of
mortality and adverse events after CABG<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. In the EuroSCORE model, 60 years of age was
accepted as a cut-off value, thus one point was assigned per each five years above
60 years. In the CHA<sub>2</sub>DS<sub>2</sub>-VASc score, one point was assigned
for 65-75 of age years and two points were assigned for age &#x02265; 75 years.
Compatible with previous studies, our study demonstrated an association between age
and MACE<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p>Heart transplantation (HT) and DM are not included in the EuroSCORE risk model. On
the other hand, HT, DM, and age were the predominant variables causing high scores
in our study. Age and HT were independent predictors for MACE in the present study.
Although several studies revealed that patients with DM are at high risk for MACE
and death after CABG, univariate analysis revealed that DM was not an independent
predictor for MACE in the present study, like studies by Rajakaruna et
al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>.
These conflicting data may be related to defining the criteria of DM. DM was defined
as the need for insulin or oral medication in the present study, while another study
defined DM as the need for diet, oral medication, or insulin
therapy<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>.
Patients with insulin-dependent DM have a significantly higher rate of mortality and
MACE than those with non-insulin-dependent DM<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. We also did not classify DM as
insulin-dependent or non-dependent. These might explain the different outcome
associated with diabetes on early mortality in the present study.</p><p>Although there is conflicting data in the literature, we showed that preexisting HT
is a poor predictor for patients undergoing isolated CABG<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>. CABG has been shown to be
superior to medical therapy alone in patients with preoperative low
LVEF<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>.
Besides, Dalen et al. showed that the reduced ejection fraction doubled the risk of
early postoperative death<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>. Compatible with the previous studies, patients with
left ventricular systolic dysfunction and symptoms of heart failure had
significantly high in-hospital mortality and morbidity in our
study<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p>Similar to our study, numerous studies have demonstrated that the PVD was an
independent predictor of early mortality and poor short-term outcome after
CABG<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. On
the other hand, the association between PVD and early mortality was not confirmed in
some studies<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>.</p><p>History of stroke has been found to be associated with mortality and increased early
and late postoperative stroke<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. In line with the literature, the present study
demonstrated that a history of preoperative stroke was associated with poor
outcome.</p><p>Consequently, when we performed univariate analysis of each
CHA<sub>2</sub>DS<sub>2</sub>-VASc score component, congestive heart failure or
ejection fraction &#x0003c; 40%, age, hypertension, cerebrovascular accident, and PVD
were significantly associated with MACE in patients undergoing after isolated CABG,
whereas DM and sex were not.</p><p>Several studies have demonstrated an association between the
CHA<sub>2</sub>DS<sub>2</sub>-VASc score and increased mortality and non-fatal
adverse cardiovascular outcomes in different clinical conditions, regardless of the
presence of AF<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>.
Recently, Hamid et al. observed high mortality in the patients undergoing
transcatheter aortic valve replacement who had CHA<sub>2</sub>DS<sub>2</sub>-VASc
score &#x0003e; 6. Therefore CHA<sub>2</sub>DS<sub>2</sub>-VASc score was proposed as a
simple tool for the identification of high-risk patients for short-term and mid-term
mortalities in patients undergoing transcatheter aortic valve replacement
(TAVR)<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>.</p><p>This the first study which aimed to investigate the value of
CHA<sub>2</sub>DS<sub>2</sub>-VASc score to estimate MACE in patients undergoing
isolated CABG surgery. Biancari et al. demonstrated predictive accuracy of
CHA<sub>2</sub>DS<sub>2</sub>-VASc score for immediate and late stroke in
patients after CABG without pre- and postoperative AF. They also demonstrated that
CHA<sub>2</sub>DS<sub>2</sub>-VASc score is a predictor for late all-cause
mortality and cardiovascular mortality<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. But there is no data specifically evaluating the
value of CHA<sub>2</sub>DS<sub>2</sub>-VASc score for prediction of in-hospital
mortality and MACE in patients undergoing isolated CABG.</p><sec><title>Limitation</title><p>The major limitation of our study is that we focused on the
CHA<sub>2</sub>DS<sub>2</sub>-VASc score, which only includes the
preoperative variables, and we did not take operative and postoperative
variables into account. In the recent years, more complex preoperative patient
profile was being referred for CABG due to improved medical treatment options
and achievements of interventional cardiology. As preoperative variables may
have limited predictor role without combination with operative and postoperative
variables, larger studies including preoperative, operative, and postoperative
variables are required. The second limitation was that the surgery was performed
by a particular surgeon group. And another limitation is the retrospective
nature of the study. So this study is single-centered and may not be generalized
to all patient groups.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>We showed that CHA<sub>2</sub>DS<sub>2</sub>-VASc score may predict in-hospital
mortality and MACE in patients undergoing isolated CABG in our study population.
CHA<sub>2</sub>DS<sub>2</sub>-VASc score is a handy risk stratification score
and easily appliable at bedside without any computational software. Further studies
are required to assess the validity of our findings in larger populations.</p><table-wrap id="t7" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors&#x02019; roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;MK</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SO</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MZ</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published.</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="supported-by"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frye</surname><given-names>RL</given-names></name><name><surname>August</surname><given-names>P</given-names></name><name><surname>Brooks</surname><given-names>MM</given-names></name><name><surname>Hardison</surname><given-names>RM</given-names></name><name><surname>Kelsey</surname><given-names>SF</given-names></name><name><surname>MacGregor</surname><given-names>JM</given-names></name></person-group><person-group person-group-type="author"><collab>BARI 2D Study Group</collab></person-group><article-title>A randomized trial of therapies for type 2 diabetes and coronary
artery disease</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><issue>24</issue><fpage>2503</fpage><lpage>2515</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0805796</pub-id><pub-id pub-id-type="pmid">19502645</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohr</surname><given-names>FW</given-names></name><name><surname>Morice</surname><given-names>MC</given-names></name><name><surname>Kappetein</surname></name><name><surname>Feldman</surname><given-names>TE</given-names></name><name><surname>St&#x000e5;hle</surname><given-names>E</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name></person-group><article-title>Coronary artery bypass graft surgery versus percutaneous coronary
intervention in patients with three-vessel disease and left main coronary
disease 5-year follow-up of the randomised, clinical SYNTAX
trial</article-title><source>Lancet</source><year>2013</year><volume>381</volume><issue>9867</issue><fpage>629</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)60141-5</pub-id><pub-id pub-id-type="pmid">23439102</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahian</surname><given-names>DM</given-names></name><name><surname>O'Brien</surname><given-names>SM</given-names></name><name><surname>Filardo</surname><given-names>G</given-names></name><name><surname>Ferraris</surname><given-names>VA</given-names></name><name><surname>Haan</surname><given-names>CK</given-names></name><name><surname>Rich</surname><given-names>JB</given-names></name></person-group><person-group person-group-type="author"><collab>Society of Thoracic Surgeons Quality Measurement Task Force</collab></person-group><article-title>The society of thoracic surgeons 2008 cardiac surgery risk models
part 1 - coronary artery bypass grafting surgery</article-title><source>Ann Thorac Surg</source><year>2009</year><volume>88</volume><issue>1 Suppl</issue><fpage>S2</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2009.05.053</pub-id><pub-id pub-id-type="pmid">19559822</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karim</surname><given-names>MN</given-names></name><name><surname>Reid</surname><given-names>CM</given-names></name><name><surname>Cochrane</surname><given-names>A</given-names></name><name><surname>Tran</surname><given-names>L</given-names></name><name><surname>Alramadan</surname><given-names>M</given-names></name><name><surname>Hossain</surname><given-names>MN</given-names></name></person-group><article-title>Mortality risk prediction models for coronary artery bypass graft
surgery current scenario and future direction</article-title><source>J Cardiovasc Surg</source><year>2017</year><volume>58</volume><issue>6</issue><fpage>931</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.23736/S0021-9509.17.09965-7</pub-id><pub-id pub-id-type="pmid">28497663</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cetin</surname><given-names>M</given-names></name><name><surname>Cakici</surname><given-names>M</given-names></name><name><surname>Zencir</surname><given-names>C</given-names></name><name><surname>Tasolar</surname><given-names>H</given-names></name><name><surname>Baysal</surname><given-names>E</given-names></name><name><surname>Balli</surname><given-names>M</given-names></name></person-group><article-title>Prediction of coronary artery disease severity using CHADS2 and
CHA2DS2-VASc scores and a newly defined CHA2DS2-VASc-HS
score</article-title><source>Am J Cardiol</source><year>2014</year><volume>113</volume><issue>6</issue><fpage>950</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2013.11.056</pub-id><pub-id pub-id-type="pmid">24444782</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>SK</given-names></name><name><surname>Lo</surname><given-names>HM</given-names></name><name><surname>Chiu</surname><given-names>CZ</given-names></name><name><surname>Shyu</surname><given-names>KG</given-names></name></person-group><article-title>CHA2DS2-VASc score predicts intracoronary thrombus burden in
patients with ST-elevation myocardial infarction</article-title><source>Biomed Res</source><year>2017</year><volume>28</volume><issue>18</issue><fpage>8050</fpage><lpage>8054</lpage></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biancari</surname><given-names>F</given-names></name><name><surname>Asim Mahar</surname><given-names>MA</given-names></name><name><surname>Kangasniemi</surname><given-names>OP</given-names></name></person-group><article-title>CHADS2 and CHA2DS2-VASc scores for prediction of immediate and
late stroke after coronary artery bypass graft surgery</article-title><source>J Stroke Cerebrovasc Dis</source><year>2013</year><volume>22</volume><issue>8</issue><fpage>1304</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2012.11.004</pub-id><pub-id pub-id-type="pmid">23253529</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antunes</surname><given-names>PE</given-names></name><name><surname>de Oliveira</surname><given-names>JF</given-names></name><name><surname>Antunes</surname><given-names>MJ</given-names></name></person-group><article-title>Risk-prediction for postoperative major morbidity in coronary
surgery</article-title><source>Eur J Cardiothorac Surg</source><year>2009</year><volume>35</volume><issue>5</issue><fpage>760</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1016/j.ejcts.2008.10.046</pub-id><pub-id pub-id-type="pmid">19243970</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamal</surname><given-names>YA</given-names></name><name><surname>Al-Elwany</surname><given-names>S</given-names></name><name><surname>Ghoneim</surname><given-names>A</given-names></name><name><surname>El-Minshawy</surname><given-names>A</given-names></name></person-group><article-title>Traditional predictors of in-hospital mortality after coronary
artery bypass grafting Current status</article-title><source>Cardiothorac Vasc Sci</source><year>2017</year><volume>1</volume><issue>2</issue><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.15761/CVS.1000107</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ad</surname><given-names>N</given-names></name><name><surname>Barnett</surname><given-names>SD</given-names></name><name><surname>Speir</surname><given-names>AM</given-names></name></person-group><article-title>The performance of the EuroSCORE and the society of thoracic
surgeons mortality risk score the gender factor</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2007</year><volume>6</volume><issue>2</issue><fpage>192</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1510/icvts.2006.138313</pub-id><pub-id pub-id-type="pmid">17669807</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamal</surname><given-names>YA</given-names></name><name><surname>Al-Elwany</surname><given-names>SE</given-names></name><name><surname>Ghoneim</surname><given-names>A</given-names></name><name><surname>El-Minshawy</surname><given-names>AK</given-names></name></person-group><article-title>Predictors of early adverse events after isolated coronary artery
bypass grafting: Current status</article-title><source>Austin J Clin Cardiolog [Internet]</source><year>2017</year><date-in-citation content-type="access-date">2019 Apr 27</date-in-citation><volume>4</volume><issue>2</issue><fpage>1059</fpage><lpage>1059</lpage><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://austinpublishinggroup.com/clinical-cardiology/fulltext/ajcc-v4-id1059.pdf">http://austinpublishinggroup.com/clinical-cardiology/fulltext/ajcc-v4-id1059.pdf</ext-link></comment></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>M</given-names></name><name><surname>Bandeali</surname><given-names>SJ</given-names></name><name><surname>Kayani</surname><given-names>WT</given-names></name><name><surname>Ahmad</surname><given-names>W</given-names></name><name><surname>Shahzad</surname><given-names>SA</given-names></name><name><surname>Jneid</surname><given-names>H</given-names></name></person-group><article-title>Comparison by meta-analysis of mortality after isolated coronary
artery bypass grafting in women versus men</article-title><source>Am J Cardiol</source><year>2013</year><volume>112</volume><issue>3</issue><fpage>309</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2013.03.034</pub-id><pub-id pub-id-type="pmid">23642381</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faerber</surname><given-names>G</given-names></name><name><surname>Zacher</surname><given-names>M</given-names></name><name><surname>Reents</surname><given-names>W</given-names></name><name><surname>Boergermann</surname><given-names>J</given-names></name><name><surname>Kappert</surname><given-names>U</given-names></name><name><surname>Boening</surname><given-names>A</given-names></name></person-group><article-title>Female sex is not a risk factor for post procedural mortality in
coronary bypass surgery in the elderly A secondary analysis of the GOPCABE
trial</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><issue>8</issue><elocation-id>e0184038</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0184038</pub-id><pub-id pub-id-type="pmid">28854266</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safaie</surname><given-names>N</given-names></name><name><surname>Montazerghaem</surname><given-names>H</given-names></name><name><surname>Jodati</surname><given-names>A</given-names></name><name><surname>Maghamipour</surname><given-names>N</given-names></name></person-group><article-title>In-hospital complications of coronary artery bypass graft surgery
in patients older than 70 years</article-title><source>J Cardiovasc Thorac Res</source><year>2015</year><volume>7</volume><issue>2</issue><fpage>60</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.15171/jcvtr.2015.13</pub-id><pub-id pub-id-type="pmid">26191393</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajakaruna</surname><given-names>C</given-names></name><name><surname>Rogers</surname><given-names>CA</given-names></name><name><surname>Suranimala</surname><given-names>C</given-names></name><name><surname>Angelini</surname><given-names>GD</given-names></name><name><surname>Ascione</surname><given-names>R</given-names></name></person-group><article-title>The effect of diabetes mellitus on patients undergoing coronary
surgery a risk-adjusted analysis</article-title><source>J Thorac Cardiovasc Surg</source><year>2006</year><volume>132</volume><issue>4</issue><fpage>802</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2006.05.056</pub-id><pub-id pub-id-type="pmid">17000291</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szab&#x000f3;</surname><given-names>Z</given-names></name><name><surname>H&#x000e5;kanson</surname><given-names>E</given-names></name><name><surname>Svedjeholm</surname><given-names>R</given-names></name></person-group><article-title>Early postoperative outcome and medium-term survival in 540
diabetic and 2239 nondiabetic patients undergoing coronary artery bypass
grafting</article-title><source>Ann Thorac Surg</source><year>2002</year><volume>74</volume><issue>3</issue><fpage>712</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1016/S0003-4975(02)03778-5</pub-id><pub-id pub-id-type="pmid">12238829</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raza</surname><given-names>S</given-names></name><name><surname>Sabik</surname><given-names>JF</given-names></name><name><surname>Ainkaran</surname><given-names>P</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name></person-group><article-title>Coronary artery bypass grafting in diabetics a growing health
care cost crisis</article-title><source>J Thorac Cardiovasc Surg</source><year>2015</year><volume>150</volume><issue>2</issue><fpage>304</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2015.03.041</pub-id><pub-id pub-id-type="pmid">26027913</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vavlukis</surname><given-names>M</given-names></name><name><surname>Borozanov</surname><given-names>V</given-names></name><name><surname>Georgievska-Ismail</surname><given-names>LJ</given-names></name><name><surname>Bosevski</surname><given-names>M</given-names></name><name><surname>Taneva</surname><given-names>B</given-names></name><name><surname>Kostova</surname><given-names>N</given-names></name><etal/></person-group><article-title>Arterial hypertension in patients with coronary artery disease
treated with surgical myocardial revascularization</article-title><source>Bratisl Lek Listy [Internet]</source><year>2007</year><date-in-citation content-type="access-date">2019 Apr 27</date-in-citation><volume>108</volume><issue>7</issue><fpage>301</fpage><lpage>306</lpage><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://core.ac.uk/download/pdf/35341402.pdf">https://core.ac.uk/download/pdf/35341402.pdf</ext-link></comment></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrobel</surname><given-names>K</given-names></name><name><surname>Stevens</surname><given-names>SR</given-names></name><name><surname>Jones</surname><given-names>RH</given-names></name><name><surname>Selzman</surname><given-names>CH</given-names></name><name><surname>Lamy</surname><given-names>A</given-names></name><etal/></person-group><article-title>Influence of baseline characteristics, operative conduct and
postoperative course on 30-day outcomes of coronary artery bypass grafting
among patients with left ventricular dysfunction: results from the surgical
treatment for ischemic heart failure (STICH) trial</article-title><source>Circulation</source><year>2015</year><volume>25;132</volume><issue>8</issue><fpage>720</fpage><lpage>730</lpage><ext-link ext-link-type="uri" xlink:href="10.1161/CIRCULATIONAHA.114.014932">10.1161/CIRCULATIONAHA.114.014932</ext-link></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalen</surname><given-names>M</given-names></name><name><surname>Lund</surname><given-names>LH</given-names></name><name><surname>Ivert</surname><given-names>T</given-names></name><name><surname>Holzmann</surname><given-names>MJ</given-names></name><name><surname>Sartipy</surname><given-names>U</given-names></name></person-group><article-title>Survival after coronary artery bypass grafting in patients with
preoperative heart failure and preserved vs reduced ejection
fraction</article-title><source>JAMA Cardiol</source><year>2016</year><volume>1</volume><issue>5</issue><fpage>530</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2016.1465</pub-id><pub-id pub-id-type="pmid">27434816</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birkmeyer</surname><given-names>JD</given-names></name><name><surname>O'Connor</surname><given-names>GT</given-names></name><name><surname>Quinton</surname><given-names>HB</given-names></name><name><surname>Ricci</surname><given-names>MA</given-names></name><name><surname>Morton</surname><given-names>JR</given-names></name><name><surname>Leavitt</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>The effect of peripheral vascular disease on in-hospital
mortality rates with coronary artery bypass surgery</article-title><source>Northern New England Cardiovascular Disease Study Group. J Vasc Surg
[Internet]</source><year>1995</year><date-in-citation content-type="access-date">2019 Apr 27</date-in-citation><volume>21</volume><issue>3</issue><fpage>445</fpage><lpage>452</lpage><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/7877226">https://www.ncbi.nlm.nih.gov/pubmed/7877226</ext-link></comment></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Straten</surname><given-names>AH</given-names></name><name><surname>Firanescu</surname><given-names>C</given-names></name><name><surname>Soliman Hamad</surname><given-names>MA</given-names></name><name><surname>Tan</surname><given-names>ME</given-names></name><name><surname>Woorst</surname><given-names>JF</given-names></name><name><surname>Martens</surname><given-names>EJ</given-names></name></person-group><article-title>Peripheral vascular disease as a predictor of survival after
coronary artery bypass grafting comparison with a matched general
population</article-title><source>Ann Thorac Surg</source><year>2010</year><volume>89</volume><issue>2</issue><fpage>414</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2009.11.036</pub-id><pub-id pub-id-type="pmid">20103313</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anyanwu</surname><given-names>AC</given-names></name><name><surname>Filsoufi</surname><given-names>F</given-names></name><name><surname>Salzberg</surname><given-names>SP</given-names></name><name><surname>Bronster</surname><given-names>DJ</given-names></name><name><surname>Adams</surname><given-names>DH</given-names></name></person-group><article-title>Epidemiology of stroke after cardiac surgery in the current
era</article-title><source>J Thorac Cardiovasc Surg</source><year>2007</year><volume>134</volume><issue>5</issue><fpage>1121</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2007.06.031</pub-id><pub-id pub-id-type="pmid">17976438</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puurunen</surname><given-names>MK</given-names></name><name><surname>Kiviniemi</surname><given-names>T</given-names></name><name><surname>Schlitt</surname><given-names>A</given-names></name><name><surname>Rubboli</surname><given-names>A</given-names></name><name><surname>Dietrich</surname><given-names>B</given-names></name><name><surname>Karjalainen</surname><given-names>P</given-names></name></person-group><article-title>CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in
patients with atrial fibrillation undergoing percutaneous coronary
intervention</article-title><source>Thromb Res</source><year>2014</year><volume>133</volume><issue>4</issue><fpage>560</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2014.01.007</pub-id><pub-id pub-id-type="pmid">24461143</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamid</surname><given-names>T</given-names></name><name><surname>Choudhury</surname><given-names>TR</given-names></name><name><surname>Anderson</surname><given-names>SG</given-names></name></person-group><article-title>Does the CHA2DS2-VASc score predict procedural and short-term
outcomes in patients undergoing transcatheter aortic valve
implantation</article-title><source>Openheart</source><year>2015</year><volume>2</volume><issue>1</issue><elocation-id>e000170</elocation-id><pub-id pub-id-type="doi">10.1136/openhrt-2014-000170</pub-id><pub-id pub-id-type="pmid">26512326</pub-id></element-citation></ref></ref-list></back></article>